Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1

Conditions

Carcinoma, Hepatocellular 59Cholangiocarcinoma 19Carcinoma, Renal Cell 16Biliary Tract Neoplasms 11Stomach Neoplasms 9Thyroid Neoplasms 8Endometrial Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 7Melanoma 6Uterine Cervical Neoplasms 5Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Cirrhosis, Familial, with Pulmonary Hypertension 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Vulvar Neoplasms 2Uveal Melanoma 2Triple Negative Breast Neoplasms 2Thymoma 2Solid Tumors 2

Interventions

Oxaliplatin 26Gemcitabine 22Fluorouracil 17Capecitabine 16Leucovorin 15pembrolizumab 14Docetaxel 14Cisplatin 13Bevacizumab 12Radiotherapy 8Paclitaxel 8Irinotecan 8Trastuzumab 7Pemetrexed 6Carboplatin 6130-nm albumin-bound paclitaxel 6durvalumab 5cemiplimab 5Erlotinib Hydrochloride 5Sunitinib 4Ramucirumab 4Metformin 4Gefitinib 4trastuzumab deruxtecan 3tislelizumab 3cabozantinib 3atezolizumab 3Taxes 3Sorafenib 3Panitumumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma × lenvatinib × Clear all
NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Erasmus Medical Center

Phase 2 Not yet recruiting
87 enrolled
Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms

NCT04699071 2021-10-21

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

National University Hospital, Singapore

Phase 2 Unknown
10 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡